Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

(March 29, 2026) by Reuters

In March 2026, Eli Lilly signed a global licensing deal worth up to $2.75 billion. The partnership utilizes Insilico’s AI platform to develop novel oral therapeutics, including a preclinical GLP-1 candidate for diabetes.Eli Lilly & Insilico Medicine: A $2.75 Billion Strategic AI-Driven Partnership

Pharmaceutical companies are increasingly turning ​to AI to accelerate R&D, betting on ​new modelling tools and automated labs to ⁠unlock efficiency gains across their pipeline, and in ​line with a push by the U.S. Food ​and Drug Administration to reduce animal testing in the near future.